Sabal Trust CO Trims Position in Johnson & Johnson (NYSE:JNJ)

Sabal Trust CO reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 266,276 shares of the company’s stock after selling 1,379 shares during the quarter. Johnson & Johnson accounts for approximately 2.6% of Sabal Trust CO’s portfolio, making the stock its 7th largest holding. Sabal Trust CO’s holdings in Johnson & Johnson were worth $41,736,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Narwhal Capital Management boosted its holdings in shares of Johnson & Johnson by 8.9% during the fourth quarter. Narwhal Capital Management now owns 99,467 shares of the company’s stock worth $15,590,000 after purchasing an additional 8,106 shares during the period. Joel Isaacson & Co. LLC boosted its holdings in shares of Johnson & Johnson by 4.7% during the fourth quarter. Joel Isaacson & Co. LLC now owns 71,197 shares of the company’s stock worth $11,159,000 after purchasing an additional 3,209 shares during the period. Capital Management Associates Inc purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth about $653,000. DekaBank Deutsche Girozentrale lifted its holdings in Johnson & Johnson by 4.8% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 4,396,416 shares of the company’s stock worth $688,198,000 after buying an additional 200,193 shares during the period. Finally, Tritonpoint Wealth LLC purchased a new stake in Johnson & Johnson in the fourth quarter worth about $13,984,000. 69.55% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have commented on JNJ. Royal Bank of Canada restated an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday, February 28th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Morgan Stanley decreased their target price on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 24th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, March 13th. Finally, Raymond James raised their target price on shares of Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Seven equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $177.31.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the transaction, the executive vice president now directly owns 141,416 shares in the company, valued at approximately $22,099,078.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares in the company, valued at $105,810,030.75. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Jennifer L. Taubert sold 59,397 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the transaction, the executive vice president now owns 141,416 shares in the company, valued at $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Stock Down 0.9 %

Shares of JNJ stock opened at $148.78 on Friday. The company’s fifty day simple moving average is $157.42 and its two-hundred day simple moving average is $156.08. Johnson & Johnson has a 52 week low of $144.95 and a 52 week high of $175.97. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.38. The stock has a market cap of $358.53 billion, a P/E ratio of 10.77, a PEG ratio of 2.55 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, topping analysts’ consensus estimates of $2.28 by $0.01. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The firm had revenue of $21.40 billion for the quarter, compared to the consensus estimate of $21.02 billion. During the same period in the previous year, the firm posted $2.35 EPS. The business’s quarterly revenue was down 9.7% on a year-over-year basis. Analysts predict that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.